• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Study P521-01


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Completed
Application Number /
Requirement Number
P020012 / PAS001
Date Original Protocol Accepted 10/27/2006
Date Current Protocol Accepted 10/27/2006
Study Name Study P521-01
Device Name ARTEFILL, BELLAFILL PMMA COLLAGEN PERMANENT DERMAL FILLER
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Objectives This is a multi-center, non-randomized, non-controlled post-approval study.
Study Population Subjects who agree to participate and are consecutively treated with Artefill in nasolabial folds (NLF). All subjects must have a negative Artefill skin
test prior to treatment.
Sample Size The sample size is 1,000 subjects who agree to participate and are consecutively treated with ArteFill in nasolabial folds. There are to be 25 investigational sites.
Key Study Endpoints Endpoints include the incidence of granuloma, incidence of serious unanticipated adverse events (including their severity and relation to the implant product), incidence of anticipated adverse events at each follow-up, and subject's assessment of satisfaction characterized by using a five point non-parametric scale at each follow-up.
Follow-up Visits and Length of Follow-up 5 years
Patients will be evaluated at baseline before treatment is administered. Follow-up starts at the completion of treatments. The first follow-up visit is at a 3 months after the last treatment, and then using a mail patient questionnaire the sponsor will assess adverse events and subject's satisfaction with treatment at the following intervals from the last treatment:
6, 12, and 18 months, and then 2, 3, 4 and 5 years. at the end of 5 years of follow-up, a final office visit is conducted. During the follow-up period, if a subject indicates the presence of a potential adverse event of a
questionnaire, the sponsor or its representative will contact the investigator caring for that subject. For serious adverse events related to the treatment, the investigator will contact the subject to schedule an appointment to have the event evaluated clinically at the site in a timely manner.
Interim or Final Data Summary
Actual Number of Patients Enrolled 1,008
Actual Number of Sites Enrolled 23
Patient Follow-up Rate 87% at 5 years
Final Safety Findings Granulomas were encountered in 17 of 1,008 subjects (1.69%). A total of 887 adverse events (AEs) were
noted among 416 (41.3%) treated subjects. There were 177 AEs among 118 (11.7%) treated subjects that were considered device쳌]related. In general, the majority of these events were typical of dermal fillers, mild in severity and resolved during the study period. A total of 101 serious adverse events (SAEs) were noted among 75 (7.4%) treated subjects. In addition to the 7 deaths, there were 94 other SAEs.
The 94 other serious adverse events included one event of difficulty breathing, shortness of breath, or
tightness in the chest, four events of severe illness or trauma, 43 other local complications, and 46 other systemic complications. None of these SAEs were determined to be device쳌]related.
Final Effect Findings Subject satisfaction remained high throughout the study. The majority (>83%) of subjects were very satisfied or satisfied (scored 1 or 2 on the 5쳌]point scale) with their treatment outcome at the 5쳌 year follow ]up.
Study Strengths & Weaknesses This is a prospective, multicenter study that provides long term data up to 5 years on the safety and effectiveness of the device. The follow ]up rate at 5 years was relatively high (87%). The weakness of the study was the lack of a comparison group.
Recommendations for Labeling Changes The labeling will be updated based on the 5쳌 year safety and effectiveness results reported in the PAS
final report.


Study P521-01 Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 10/27/2007 11/09/2007 Overdue/Received
2 year report 10/26/2008 10/27/2008 Overdue/Received
3 year report 10/26/2009 10/28/2009 Overdue/Received
4 year report 10/26/2010 10/26/2010 On Time
5 year report 10/26/2011 10/28/2011 Overdue/Received
6 year report 10/25/2012 10/25/2012 On Time
7 year report 10/25/2013 10/28/2013 Overdue/Received
final report 05/14/2014 05/20/2014 Overdue/Received


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-